B-Raf

Summary

Gene Symbol: B-Raf
Description: B-Raf proto-oncogene, serine/threonine kinase
Alias: B-RAF1, B-raf, BRAF1, NS7, RAFB1, serine/threonine-protein kinase B-raf, 94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-raf murine sarcoma viral oncogene homolog B1
Species: human

Top Publications

  1. doi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
  2. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
  3. ncbi Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    Paul T C Wan
    Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
    Cell 116:855-67. 2004
  4. pmc Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    Nikhil Wagle
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
    J Clin Oncol 29:3085-96. 2011
  5. doi Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
    David Capper
    Department of Neuropathology, Institute of Pathology, Ruprecht Karls University, Heidelberg, Germany
    Acta Neuropathol 123:223-33. 2012
  6. ncbi High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
    Edna T Kimura
    Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    Cancer Res 63:1454-7. 2003
  7. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
  8. ncbi BRAF and RAS mutations in human lung cancer and melanoma
    Marcia S Brose
    Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Cancer Res 62:6997-7000. 2002
  9. ncbi BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
    Marina N Nikiforova
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45267, USA
    J Clin Endocrinol Metab 88:5399-404. 2003
  10. pmc Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
    Frank A Sinicrope
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 119:2765-70. 2013

Research Grants

  1. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2012
  2. SBIR 2009 TOPIC 255- TITLE: PYRIDINOPYRIMIDE ANALOGS
    Weibo Wang; Fiscal Year: 2009
  3. NATHANAEL SCHIANDER GRAY; Fiscal Year: 2015
  4. Vernon K Sondak; Fiscal Year: 2016
  5. A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery
    JEFFREY ALLEN KNAUF; Fiscal Year: 2010
  6. Vasiliki Poulaki; Fiscal Year: 2016
  7. Autophagy in epidermal melanocyte: a protective or a destructive role?
    Vijayasaradhi Setaluri; Fiscal Year: 2013
  8. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2009
  9. Blood-based detection of BRAF DNA as a biomarker in metastatic melanoma patients
    David Polsky; Fiscal Year: 2012
  10. BONNIE ELYSSA GOULDROTHBERG; Fiscal Year: 2014

Detail Information

Publications400 found, 100 shown here

  1. doi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  2. doi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy...
  3. ncbi Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    Paul T C Wan
    Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK
    Cell 116:855-67. 2004
    ..The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism...
  4. pmc Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    Nikhil Wagle
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
    J Clin Oncol 29:3085-96. 2011
    ..These results provide an instructive framework for assessing mechanisms of acquired resistance to kinase inhibition and illustrate the use of emerging technologies in a manner that may accelerate personalized cancer medicine...
  5. doi Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
    David Capper
    Department of Neuropathology, Institute of Pathology, Ruprecht Karls University, Heidelberg, Germany
    Acta Neuropathol 123:223-33. 2012
    ..An integrated approach combining both, VE1 immunohistochemistry and genetic analysis may increase the diagnostic accuracy of BRAF mutation analysis...
  6. ncbi High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
    Edna T Kimura
    Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    Cancer Res 63:1454-7. 2003
    ..Because these signaling proteins function along the same pathway in thyroid cells, this represents a unique paradigm of human tumorigenesis through mutation of three signaling effectors lying in tandem...
  7. doi Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    Georgina V Long
    Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia
    J Clin Oncol 29:1239-46. 2011
    ..To assess the frequency and type of oncogenic BRAF mutations in metastatic melanoma and correlate BRAF status with clinicopathologic features and outcome...
  8. ncbi BRAF and RAS mutations in human lung cancer and melanoma
    Marcia S Brose
    Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Cancer Res 62:6997-7000. 2002
    ..Although uncommon, BRAF mutations in human lung cancers may identify a subset of tumors sensitive to targeted therapy...
  9. ncbi BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas
    Marina N Nikiforova
    Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45267, USA
    J Clin Endocrinol Metab 88:5399-404. 2003
    ..They are associated with distinct phenotypical and biological properties of papillary carcinomas and may participate in progression to poorly differentiated and anaplastic carcinomas...
  10. pmc Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
    Frank A Sinicrope
    Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Cancer 119:2765-70. 2013
    ..We used a mutation-specific antibody to examine mutant BRAFV600E protein expression and its concordance with BRAFV600E mutation data...
  11. doi Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma
    Cheryl A Adackapara
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Histopathology 63:187-93. 2013
    ..A BRAF V600E-specific antibody has recently become commercially available. The aim of this study was to determine whether immunohistochemistry can predict BRAF mutations in CRC...
  12. ncbi Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
    Harith Rajagopalan
    Sidney Kimmel Comprehensive Cancer Centre, Howard Hughes Medical Institution and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Nature 418:934. 2002
    ....
  13. doi Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
    Alexander M Menzies
    Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia
    Clin Cancer Res 18:3242-9. 2012
    ..This study sought to determine the BRAF mutation status by age-decade and whether BRAF-mutant genotypes correlated with clinicopathologic features and outcome in patients with metastatic melanoma...
  14. doi Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
    Jolien Tol
    Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Eur J Cancer 46:1997-2009. 2010
    ..Here we assess the predictive value of other potential relevant markers involved in the epidermal growth factor receptor (EGFR) signalling pathways for response to cetuximab-based treatment...
  15. pmc COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
    Cory M Johannessen
    Broad Institute of Harvard and Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Nature 468:968-72. 2010
    ....
  16. ncbi BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, Maryland 21287, USA
    J Clin Endocrinol Metab 90:6373-9. 2005
    ..Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer...
  17. doi Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
    Cecily P Vaughn
    ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, USA
    Genes Chromosomes Cancer 50:307-12. 2011
    ....
  18. doi Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer
    Gordon Hutchins
    Leeds Institute of Molecular Medicine, Leeds University, United Kingdom
    J Clin Oncol 29:1261-70. 2011
    ..We investigated the usefulness of defective mismatch repair (dMMR), BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy...
  19. doi Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
    Arnaud D Roth
    Oncosurgery, Geneva UniversityHospital, Geneva, Switzerland
    J Clin Oncol 28:466-74. 2010
    ..We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting...
  20. doi The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
    A Fariña-Sarasqueta
    Department of Molecular Diagnostics, Catharina Hospital Eindhoven, The Netherlands
    Ann Oncol 21:2396-402. 2010
    ..We determined the effects on clinical outcome of the BRAF mutation, microsatellite instability (MSI) and KRAS mutations in stage II and stage III colon carcinoma...
  21. pmc Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
    Amy J French
    Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, 920 Hilton Building, Rochester, MN 55905, USA
    Clin Cancer Res 14:3408-15. 2008
    ..Although the presence of dMMR seems to be a favorable prognostic marker, data suggest that these patients do not respond as well to adjuvant chemotherapy...
  22. doi BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study
    Rossella Elisei
    Department of Endocrinology, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy
    J Clin Endocrinol Metab 93:3943-9. 2008
    ..In this study we verified the prognostic value of the BRAF(V600E) mutation in PTC patients with a long-term follow-up...
  23. doi Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
    Genevieve Schindler
    Department of Neurosurgery, Medical Faculty of the Ruprecht Karls University Heidelberg, Mannheim, Germany
    Acta Neuropathol 121:397-405. 2011
    ..Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies...
  24. pmc Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients
    Hong Shen
    Department of Oncology, Second Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310009, Zhejiang Province, China
    World J Gastroenterol 17:809-16. 2011
    ..To identify and assess mutations in the K-ras and BRAF genes in a cohort of Chinese patients with colorectal cancer (CRC) for their association with various clinicopathological parameters and prognosis...
  25. pmc Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
    F Xing
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Oncogene 31:446-57. 2012
    ....
  26. pmc BRAFV600E negatively regulates the AKT pathway in melanoma cell lines
    Brenden Chen
    Discovery Oncology, Hoffmann La Roche Inc, Nutley, New Jersey, United States of America
    PLoS ONE 7:e42598. 2012
    ..Our study reveals a novel molecular mechanism underlying the regulation of feedback loops between the MAPK and AKT pathways...
  27. pmc The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis
    Gholamreza Safaee Ardekani
    Department of Dermatology and Skin Science, Jack Bell Research Centre, Vancouver Coastal Health Research Institute, University of British Columbia, Canada
    PLoS ONE 7:e47054. 2012
    ..Despite tremendous efforts made to target BRAF for cancer treatment, the correlation between BRAF mutation and patient survival is still a matter of controversy...
  28. pmc Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
    Angela J Sievert
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 110:5957-62. 2013
    ....
  29. ncbi Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis
    Ju Han Lee
    Department of Pathology, Bioinformatics Interest Group, Korea University Ansan Hospital, Ansan, Republic of Korea
    Cancer 110:38-46. 2007
    ..To address this controversy, the frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in PTC were evaluated by meta-analysis...
  30. pmc FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells
    Ethan V Abel
    Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, USA
    Cancer Res 70:2891-900. 2010
    ..These studies show that FOXD3 is suppressed by B-RAF, uncover a novel role and mechanism for FOXD3 as a negative cell cycle regulator, and have implications for the repression of melanocytic lineage cells...
  31. ncbi Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
    Gad Singer
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Natl Cancer Inst 95:484-6. 2003
    ..The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways...
  32. doi BRAF(V600E) mutation and the biology of papillary thyroid cancer
    F Frasca
    Endocrinologia, Dipartimento di Medicina Interna e Medicina Specialistica, University of Catania, PO Garibaldi Nesima, Via Palermo 636, Catania, Italy
    Endocr Relat Cancer 15:191-205. 2008
    ..These results indicate that BRAF((V600E)) mutation is a marker of aggressive disease in both micro- and macro-PTCs. Moreover, for the first time, a possible link between BRAF((V600E)) mutation and environmental carcinogens is suggested...
  33. pmc The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells
    Rosa Marina Melillo
    Istituto di Endocrinologia ed Oncologia Sperimentale del CNR G Salvatore, Dipartimento di Biologia e Patologia Cellulare e Molecolare, University Federico II, Naples, Italy
    J Clin Invest 115:1068-81. 2005
    ..Thus, motile and mitogenic properties are intrinsic to transformed thyroid cells and are governed by an epistatic oncogenic signaling cascade...
  34. pmc Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
    Anton Platz
    Department of Oncology Pathology, Karolinska Institute, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm S 17176, Sweden
    Mol Oncol 1:395-405. 2008
    ..Common alterations of the signal transducing network seem to represent molecular hallmarks of cutaneous melanomas and therefore should continue to strongly stimulate design and testing of targeted molecular interventions...
  35. pmc Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:890-900. 2012
    ..We examined the effect of BRAF mutation on survival and treatment efficacy in patients with stage III colon cancer...
  36. doi Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma
    Georgina V Long
    Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia
    Am J Surg Pathol 37:61-5. 2013
    ..Clinical use of the V600E BRAF antibody should be a valuable supplement to conventional mutation testing and allow V600E mutant metastatic melanoma patients to be triaged rapidly into appropriate treatment pathways...
  37. ncbi BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications
    Mingzhao Xing
    Division of Endocrinology and Metabolism, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Endocr Rev 28:742-62. 2007
    ..With these advances, it has become clearer that BRAF mutation will likely have significant impact on the clinical management of PTC...
  38. pmc CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 USA
    Gut 58:90-6. 2009
    ..The independent effect of CIMP, MSI and BRAF mutation on prognosis remains uncertain...
  39. pmc Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells
    Y N Vashisht Gopal
    Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 70:8736-47. 2010
    ....
  40. pmc Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
    Ben Tran
    Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia
    Cancer 117:4623-32. 2011
    ..This study investigates whether BRAF mutant CRC is further defined by a distinct pattern of metastatic spread and explores the impact of BRAF mutation and microsatellite instability (MSI) on prognosis in metastatic CRC...
  41. doi Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort
    Lu Si
    Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China
    Eur J Cancer 48:94-100. 2012
    ..Mutations of NRAS and BRAF have been described in Caucasian melanomas. However, the status and the clinical significance of BRAF and NRAS mutations in the Asian population have not been investigated on a large scale...
  42. pmc Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells
    Peng Hou
    Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Endocr Relat Cancer 18:687-97. 2011
    ..Thus, this study uncovered a prominent epigenetic mechanism through which BRAF V600E can promote PTC tumorigenesis by altering the methylation and hence the expression of numerous important genes...
  43. pmc Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 13:49. 2013
    ..We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy...
  44. doi The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations
    Giovanni Ponti
    Department of Clinical and Diagnostic Medicine and Public Health, University Hospital of Modena and Reggio Emilia, Modena, Italy
    J Clin Pathol 66:441-5. 2013
    ..However, all of them are still under treatment and disease progression free. An objective response with few side effects was observed in all patients. in vitro studies with the aim of testing drug sensitivity...
  45. pmc Epithelioid GBMs show a high percentage of BRAF V600E mutation
    Bette Kay Kleinschmidt-DeMasters
    Department of Pathology, The University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    Am J Surg Pathol 37:685-98. 2013
    ..BRAF V600E mutational analyses should be performed on E-GBMs, particularly in all pediatric and young-aged adults, given the potential for BRAF inhibitor therapy in this subset of GBM patients...
  46. doi Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study
    Kohei Fujita
    Department of Anatomic Pathology, Kyushu University, Fukuoka, Japan
    Am J Surg Pathol 35:295-304. 2011
    ..In addition, our histologic observations suggest a possible close association between SSAN and mucinous adenocarcinoma...
  47. doi Molecular analysis of multifocal papillary thyroid carcinoma
    Xiaoqi Lin
    Department of Pathology, Feinberg School of Medicine, Northwestern Memorial Hospital, Northwestern University, 251 East Huron Street, Feinberg Building 7 209C, Chicago, Illinois 60611, USA
    J Mol Endocrinol 41:195-203. 2008
    ..In conclusion, molecular analysis can separate multifocal IP PTC from ITM PTC, and may be more important than tumor size in predicting lymph node metastasis, aggressiveness, and prognosis of PTC...
  48. ncbi Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer
    M B Loughrey
    Molecular Pathology Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Fam Cancer 6:301-10. 2007
    ....
  49. pmc Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
    C S Mason
    CRC Centre for Cell and Molecular Biology, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB
    EMBO J 18:2137-48. 1999
    ..Thus, there are considerable differences between the activation of the Raf proteins; Ras-GTP mediates two phosphorylation events required for Raf-1 activation but does not regulate such events for B-Raf...
  50. pmc KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
    F Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplantes and New Technologies in Medicine, University of Pisa, Via Roma 67 56126 Pisa, Italy
    Br J Cancer 101:715-21. 2009
    ..KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutations are described in CRC...
  51. doi Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis
    Inti Zlobec
    Institute for Pathology, University Hospital of Basel, Basel, Switzerland
    Int J Cancer 127:367-80. 2010
    ..These results indicate that molecular analysis for BRAF may be a useful biomarker for identifying patients with right-sided colon cancer with poor outcome who may benefit from a more individualized course of therapy...
  52. doi Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
    Jeanne Tie
    Ludwig Colon Cancer Initiative Laboratory, Ludwig Institute for Cancer Research, Melbourne, Australia
    Int J Cancer 128:2075-84. 2011
    ..Our findings are timely and will help inform the rational development of BRAF(V600E) inhibitors in CRC...
  53. pmc BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications
    Dora Dias-Santagata
    Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e17948. 2011
    ..1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs...
  54. pmc BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors
    Kimberly Brown Dahlman
    Vanderbilt Ingram Cancer Center, Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Discov 2:791-7. 2012
    ..A patient with BRAF(L597S) mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor, TAK-733. Collectively, these data show clinical significance to BRAF(L597) mutations in melanoma...
  55. ncbi BRAF mutations in metastatic melanoma: a possible association with clinical outcome
    Rajiv Kumar
    Department of Biosciences, Karolinska Institute, Novum, 141 57 Huddinge, Sweden
    Clin Cancer Res 9:3362-8. 2003
    ..Recently, activating mutations in the BRAF gene, were reported in a large proportion of melanomas. We have studied mutations in the BRAF gene and their association with clinical parameters...
  56. pmc V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
    O M Grbovic
    Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 103:57-62. 2006
    ..Hsp90 inhibition represents a therapeutic strategy for the treatment of melanoma...
  57. pmc Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene
    Angela J Sievert
    Division of Oncology, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Brain Pathol 19:449-58. 2009
    ..Further studies are required to determine the role of this fusion gene in downstream MAPK signaling and its role in development of pediatric low-grade astrocytomas...
  58. pmc Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling
    Toshinori Hinoue
    USC Epigenome Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    PLoS ONE 4:e8357. 2009
    ..Our data will be useful for future investigations toward understanding CIMP in colorectal cancer and gaining insights into the role of aberrant DNA hypermethylation in colorectal tumorigenesis...
  59. ncbi High frequency of BRAF mutations in nevi
    Pamela M Pollock
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Bethesda, Maryland 20892, USA
    Nat Genet 33:19-20. 2003
    ..These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis...
  60. ncbi Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome
    Pablo Rodriguez-Viciana
    Comprehensive Cancer Center and Cancer Research Institute, University of California, San Francisco, CA 94115, USA
    Science 311:1287-90. 2006
    ..Our findings highlight the involvement of the MAPK pathway in human development and will provide a molecular diagnosis of CFC syndrome...
  61. ncbi KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
    ..The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment...
  62. ncbi Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma
    Nancy E Thomas
    Department of Dermatology, University of North Carolina, Chapel Hill, NC 27599, USA
    Cancer Epidemiol Biomarkers Prev 16:991-7. 2007
    ..The association of BRAF mutations with early-life UV exposure provides evidence in support of childhood sun protection for melanoma prevention...
  63. doi KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial
    Susan D Richman
    Leeds Institute of Molecular Medicine, St James s Institute of Oncology, Cancer Research UK Genomic Services, University of Leeds, Leeds, UK
    J Clin Oncol 27:5931-7. 2009
    ..We wanted to determine whether KRAS and/or BRAF mutation is also a predictive biomarker for other aCRC therapies...
  64. doi Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation
    Huisheng Wang
    Discovery Oncology, Hoffmann La Roche Inc, Nutley, New Jersey 07110, USA
    Cancer Res 71:5535-45. 2011
    ....
  65. pmc Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1
    D R Alessi
    Department of Biochemistry, University of Dundee, Scotland
    EMBO J 13:1610-9. 1994
    ....
  66. ncbi Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway
    Armelle Calipel
    Institut Biomedical des Cordeliers, INSERM U450, 15 rue de l Ecole de Medecine, 75006 Paris, France
    J Biol Chem 278:42409-18. 2003
    ..Our results pinpoint this pathway as an important component in choroidal melanoma cell lines...
  67. ncbi Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
    Tetsuya Niihori
    Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan
    Nat Genet 38:294-6. 2006
    ....
  68. pmc Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
    R E Board
    AstraZeneca Pharmaceuticals, Alderley Park, Cheshire SK10 4TG, UK
    Br J Cancer 101:1724-30. 2009
    ....
  69. ncbi The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma
    Tae Yong Kim
    Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea
    Clin Endocrinol (Oxf) 63:588-93. 2005
    ..The BRAF(V600E) mutation, the most common genetic alteration reported in papillary thyroid carcinoma, has been associated with poor prognostic factors...
  70. pmc Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors
    Bijay S Jaiswal
    Department of Molecular Biology, Genentech Inc, South San Francisco, California, United States of America
    PLoS ONE 4:e5717. 2009
    ..Understanding downstream RAS-effectors that mediate oncogenesis in a RAS mutant setting will help tailor treatments that use RAS-effector inhibitors either alone or in combination to target RAS-driven tumors...
  71. pmc Clinical correlates of NRAS and BRAF mutations in primary human melanoma
    Julie A Ellerhorst
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:229-35. 2011
    ..This study was designed to test the hypothesis that primary human cutaneous melanomas harboring mutations in NRAS or BRAF display a more aggressive clinical phenotype than tumors wild type at both loci...
  72. doi The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules
    Eun Jung Lee
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea
    Clin Endocrinol (Oxf) 75:844-50. 2011
    ..The BRAF(V600E) mutation is a useful diagnostic marker for differentiating papillary thyroid carcinoma from benign thyroid nodules, especially in BRAF(V600E) -prevalent populations such as in Korea...
  73. doi Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma
    Weibin Wang
    Cancer Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
    Ann Surg Oncol 19:31-6. 2012
    ..The purpose of this study is to compare the clinical outcomes and BRAF (V600E) mutation incidence of SBiPTC patients with those of unilateral papillary thyroid carcinoma (UiPTC) patients...
  74. doi Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration
    Hee Jung Moon
    Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea
    Ann Surg Oncol 18:792-9. 2011
    ..We investigated the diagnostic value of the BRAF(V600E) mutation of thyroid nodules according to ultrasonography (US) features and the time of BRAF(V600E) mutation analysis...
  75. ncbi Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia
    Boban Stanojevic
    Department of Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1 12 4 Sakamoto, Nagasaki 852 8523, Japan
    Endocr J 58:381-93. 2011
    ..However, it has a potential to contribute to patients stratification into high- and low-risk groups...
  76. pmc Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation
    Geoffrey K Kilili
    Molecular Cardiology Research Institute, Tufts Medical Center, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts 02111, USA
    J Biol Chem 285:15076-87. 2010
    ..Our studies reveal a more complex role for Mst2 than previously thought. The Mst2 --> LATS1/2 pathway, by maintaining PP2A-C levels, may, in some situations, positively affect mitogenic signaling...
  77. doi Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population
    Jyh Ming Liou
    Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Int J Colorectal Dis 26:1387-95. 2011
    ..Moreover, few data were available in Chinese. Therefore, we aimed to evaluate the impact of KRAS and BRAF mutations on the survival of Chinese CRC patients...
  78. doi BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy
    Alessandra Bommarito
    Sezione di Endocrinologia, Laboratorio di Endocrinologia Molecolare, Dipartimento di Biomedico di Medicina Interna e Specialistica DIBIMIS, University of Palermo, Italy
    Endocr Relat Cancer 18:669-85. 2011
    ..The recognition of this functional trilogy provides insight on how BRAF(V600E) determines cancer initiation, progression, and invasiveness in PTC, also identifying new therapeutic targets for the treatment of highly aggressive forms...
  79. pmc Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
    Raffaele Ciampi
    Department of Pathology and Laboratory Medicine and Division of Endocrinology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0529, USA
    J Clin Invest 115:94-101. 2005
    ....
  80. ncbi High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi
    Nami Ichii-Nakato
    Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
    J Invest Dermatol 126:2111-8. 2006
    ..Most of these nevi with wild-type BRAF had neroblastoma ras viral oncogene homolog mutations (9/14, 64.3%), suggesting different pathogenesis of medium-sized congenital nevi from acquired nevi and small congenital nevi...
  81. pmc The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer
    Wade S Samowitz
    Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
    Genes Chromosomes Cancer 47:835-44. 2008
    ....
  82. doi Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation
    Linwah Yip
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Surgery 146:1215-23. 2009
    ..It is not known whether pre-operative identification of BRAF mutations in cytologic specimens should alter surgical management...
  83. doi miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation
    Chen Kai Chou
    Division of Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital Kaohsiung Medical Center, Chang Gung University, Kaohsiung, Taiwan
    Thyroid 20:489-94. 2010
    ..In this study, we compared expression of deregulated miRNAs in PTCs to assess this was associated with selected clinicopathogenetic features...
  84. doi Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules
    Suk Kyeong Kim
    Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea
    Diagn Mol Pathol 17:118-25. 2008
    ..However, 10% to 30% of cases with indeterminate cytology in FNAB need other diagnostic tools to refine diagnosis...
  85. pmc B-raf, a new member of the raf family, is activated by DNA rearrangement
    S Ikawa
    Department of Oncology, University of Tokyo, Japan
    Mol Cell Biol 8:2651-4. 1988
    ..The gene was termed B-raf because it is related to but distinct from c-raf and A-raf. It appears that substitution in the amino-terminal portion of the normal B-raf protein confers transforming activity to the gene...
  86. ncbi Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer
    Joanne Young
    Conjoint Gastroenterology Laboratory, Queensland Institute of Medical Research, Herston, Australia
    Clin Gastroenterol Hepatol 3:254-63. 2005
    ..Here, we discuss their role in the development of other familial colorectal cancers (CRC). We studied non-FAP, non-HNPCC CRC families characterized by tumors that varied in their level of MSI between individual members...
  87. ncbi Suppression of BRAF(V599E) in human melanoma abrogates transformation
    Sunil R Hingorani
    Abramson Family Cancer Research Institute at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:5198-202. 2003
    ..Thus, when present, BRAF(V599E) appears to be essential for melanoma cell viability and transformation and, therefore, represents an attractive therapeutic target in the majority of melanomas that harbor the mutation...
  88. ncbi BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
    Guoren Deng
    Department of Medicine, Veteran Affairs Medical Center and Cancer Center, University of California San Francisco, California, USA
    Clin Cancer Res 10:191-5. 2004
    ..In this study, we sought to compare the frequencies of BRAF mutations in sporadic colorectal cancer with MSI with those in hereditary nonpolyposis colorectal cancer (HNPCC)...
  89. ncbi Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas
    Masaru Shinozaki
    Department Molecular Oncology, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 10:1753-7. 2004
    ..Somatic mutations of BRAF kinase, a component of the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase pathway, are frequently reported (>65%) in nevi and malignant melanomas...
  90. doi Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma
    Roland Houben
    Klinik fur Dermatologie, Venerologie und Allergologie, Julius Maximilians Universitat, Wurzburg, Germany
    J Invest Dermatol 128:2003-12. 2008
    ..Our findings suggest that mitogen-activated protein kinase (MAPK) activity is subject to regulation even in BRAF/NRAS mutant melanoma cells and that high MAPK pathway signaling may be important only in distinct subsets of tumor cells...
  91. ncbi RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis
    Raffaele Ciampi
    Department of Pathology, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    Endocrinology 148:936-41. 2007
    ..Molecular inhibitors that block RET/PTC or BRAF kinase activity have shown substantial therapeutic effects in the experimental systems and are currently being tested in clinical trials...
  92. ncbi Novel raf kinase protein-protein interactions found by an exhaustive yeast two-hybrid analysis
    Anton Yuryev
    Novartis Institute for Biomedical Research, Summit, NJ 07901, USA
    Genomics 81:112-25. 2003
    ..We propose possible functional consequences of these novel Raf interactions...
  93. ncbi B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms
    Nancy H Tran
    Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas 77030, USA
    J Biol Chem 280:16244-53. 2005
    ....
  94. ncbi Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer
    M L Maestro
    Department of Clinical Analysis, Hospital Clinico San Carlos, Madrid, Spain
    Ann Surg Oncol 14:1229-36. 2007
    ..The BRAF oncogene has been linked to the MSI pathway in tumorogenesis. The objective of this study was to determine whether alterations in BRAF are related to MSI and whether they can result in differences in survival rates...
  95. doi Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability
    Sanjay Kakar
    Department of Pathology, Veterans Affairs Medical Center and University ofCalifornia at San Francisco, San Francisco, Calif, USA
    Arch Pathol Lab Med 132:958-64. 2008
    ..The 2 chief pathways implicated in colorectal carcinogenesis, microsatellite instability and chromosomal instability, are not present in 20% to 37% of cases...
  96. pmc Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas
    David T W Jones
    Department of Pathology, Division of Molecular Histopathology, University of Cambridge, Cambridge, United Kingdom
    Cancer Res 68:8673-7. 2008
    ..This is the first report of BRAF activation through rearrangement as a frequent feature in a sporadic tumor. The frequency and specificity of this change underline its potential both as a therapeutic target and as a diagnostic tool...
  97. doi MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events
    S de Vogel
    Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
    Ann Oncol 20:1216-22. 2009
    ....
  98. pmc Polyclonality of BRAF mutations in acquired melanocytic nevi
    Jingrong Lin
    Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan
    J Natl Cancer Inst 101:1423-7. 2009
    ..The polyclonality of BRAF mutations in acquired melanocytic nevi suggests that mutation of BRAF may not be an initial event in melanocyte transformation...
  99. doi Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation
    Sun Lee
    Department of Pathology, Kyung Hee University College of Medicine, Seoul, Korea
    Pathol Int 58:104-13. 2008
    ....
  100. doi Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma
    Leisl M Packer
    Signal Transduction Team, Section of Cell and Molecular Biology, The Institute of Cancer Research, London, UK
    Pigment Cell Melanoma Res 22:785-98. 2009
    ..This study provides a basis for understanding the molecular processes that are regulated by (V600E)BRAF/MEK signalling in melanoma cells...
  101. ncbi BRAF mutation in papillary thyroid carcinoma
    Yoram Cohen
    Division of Head and Neck Cancer Research, Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 2196, USA
    J Natl Cancer Inst 95:625-7. 2003
    ..Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer...

Research Grants81

  1. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2012
    ..We expect that our studies will provide new knowledge of the molecular basis of melanoma progression, and reveal novel targets for therapeutic intervention. ..
  2. SBIR 2009 TOPIC 255- TITLE: PYRIDINOPYRIMIDE ANALOGS
    Weibo Wang; Fiscal Year: 2009
    ..The proposed analogs will be synthesized and tested against B-Raf kinases and cancer cell lines. Desirable compounds will be moved quickly to preclinical and clinical studies. ..
  3. NATHANAEL SCHIANDER GRAY; Fiscal Year: 2015
    ....
  4. Vernon K Sondak; Fiscal Year: 2016
    ....
  5. A Validated Resource of Thyroid Cancer Cell Lines for Pathway Discovery
    JEFFREY ALLEN KNAUF; Fiscal Year: 2010
    ....
  6. Vasiliki Poulaki; Fiscal Year: 2016
    ....
  7. Autophagy in epidermal melanocyte: a protective or a destructive role?
    Vijayasaradhi Setaluri; Fiscal Year: 2013
    ....
  8. SPORE in Skin Cancer
    Meenhard Herlyn; Fiscal Year: 2009
    ..CTCL is addressed in one Project and one Pilot Study, and SCC in one Pilot Study. This endeavor represents the synergistic integration of well-established individual research programs towards our collective goals. ..
  9. Blood-based detection of BRAF DNA as a biomarker in metastatic melanoma patients
    David Polsky; Fiscal Year: 2012
    ....
  10. BONNIE ELYSSA GOULDROTHBERG; Fiscal Year: 2014
    ..Thomas Lynch as Physician-in-Chief of the new cancer hospital. ..
  11. Rutao Cui; Fiscal Year: 2014
    ..Expanding our knowledge of DNA repair in different skin types provides a rich ground for melanoma prevention and for the development of targeted small-molecule therapeutics. ..
  12. B-RAF Regulation of the Cell Cycle in Melanoma
    Andrew E Aplin; Fiscal Year: 2013
    ..At the completion of our experiments, we aim to have identified new targets for therapeutic intervention to prevent aberrant melanoma cell proliferation. ..
  13. Barry Jones; Fiscal Year: 2014
    ..If ARI-4175 meets the test of feasibility in STTR Phase I, IND-enabling studies and initiation of clinical trials to investigae safety and efficacy will be proposed for Phase II. ..
  14. Pasi A Janne; Fiscal Year: 2016
    ..Findings from these studies have therapeutic implications for patients with cancers harboring genomic alterations in RET and catalyze the development of clinical trials for such patients. ..
  15. Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I
    David Polsky; Fiscal Year: 2013
    ..abstract_text> ..
  16. Walter J Storkus; Fiscal Year: 2016
    ....
  17. Boris C Bastian; Fiscal Year: 2016
    ..The goal of this project is to study its function and develop rationally-based treatment strategies and to discover the equivalent genetic alterations in the remaining 50% of uveal melanomas. ..
  18. The role of c-Met expression in melanoma growth and migration
    AMBER LEIGH SHADA; Fiscal Year: 2010
    ..Transitioning the studies of c-Met blockade in melanoma from in vitro studies to animal studies is an important step in development of targeted therapies against c-Met for metastatic melanoma in humans. ..
  19. Donita C Brady; Fiscal Year: 2015
    ..These research endeavors will solidify my training as a cancer biologist and spark novel research questions that will become the foundation for my pursuit of an academic faculty position in cancer biology. ..
  20. CRAIG LEE SLINGLUFF; Fiscal Year: 2014
    ....
  21. Molecular signatures of melanoma histology and progression: A Population Based A
    Abrar A Qureshi; Fiscal Year: 2013
    ..Evaluate genome-wide (6,000 genes) association with BRAF/NRAS/MC1R status and melanoma recurrence and mortality due to melanoma ..
  22. LEONARD IRA ZON; Fiscal Year: 2016
    ....
  23. Identifying Events and Genetic Regulators of Melanoma Progression
    CRAIG JOSEPH CEOL; Fiscal Year: 2012
    ..These studies may identify diagnostic and prognostic indicators of disease as well as therapeutic targets for cancer treatment. ..
  24. Nicholas Theodosakis; Fiscal Year: 2015
    ..New discoveries in the mechanisms underpinning metabolic changes may also suggest new metabolically-based combination therapies aimed at overcoming vemurafenib resistance. ..
  25. Nima Sharifi; Fiscal Year: 2016
    ..Furthermore, it is anticipated that similar to EGFR and BRAF mutations in lung cancer and melanoma, respectively, this work will validate mutant 3[unreadable]HSD1 as a pharmacologic target for therapy in CRPC. ..
  26. Novel AKT PH domain inhibitors to prevent skin cancer
    EMMANUELLE JOELLE MEUILLET; Fiscal Year: 2010
    ....
  27. UV damage, repair, and mutagenesis
    Gerd P Pfeifer; Fiscal Year: 2013
    ..abstract_text> ..
  28. Mario Sznol; Fiscal Year: 2016
    ..abstract_text> ..
  29. ATF2 in melanoma development and progression
    ZE apos EV A RONAI; Fiscal Year: 2012
    ..Our proposed studies will extend the use of relevant mouse melanoma models to assess ATF2 role in melanoma development and to identify and characterize the mechanisms underlying ATF2 role in the development of this tumor type. ..
  30. Repair of Clustered DNA Damages
    Yoke W Kow; Fiscal Year: 2010
    ..In addition, it will provide significant insight as to the potential mechanism involved in melanoma progression. ..
  31. MIKHAIL NIKIFOROV; Fiscal Year: 2016
    ..Therefore, we will determine OS prognostic values of C- MYC separately and in conjunction with several C-MYC targets for patients with primary melanomas and nodal melanoma metastases. ..
  32. David E Fisher; Fiscal Year: 2016
    ..Collectively we extend our deep analyses of MITF biology into a translational direction that relates melanocytic homeostasis to melanomagenesis and novel prevention strategies. ! ..
  33. The role of melanocyte precursors in zebrafish pigmentation disorders
    Richard Mark White; Fiscal Year: 2013
    ..The zebrafish has yielded important insights into the biology of these diseases, and I plan to study this fish as a tool for identifying new pathways and drugs for the treatment of these human diseases. ..
  34. Anthony N van den Pol; Fiscal Year: 2016
    ..Its highly attenuated nature reduces concerns relating to infection of normal brain tissue. If these experiments are successful, they will form a major advance toward clinical trials for metastatic melanoma in humans. ..
  35. Effect of UVA Irradiation on Melanocyte Stem Cells and Relationship to Developmen
    JAMES DOUGLAS HOERTER; Fiscal Year: 2012
    ..Understanding the early events in melanoma will permit earlier detection and development of more effective drugs to treat it and prevent it reoccurrence. ..
  36. ADHESION AND ERK SIGNALING IN MELANOMA
    Andrew E Aplin; Fiscal Year: 2013
    ..We expect that our results will prompt new therapeutic strategies for this highly aggressive cancer. ..
  37. The role of ultraviolet radiation and skin pigmentation in melanoma development
    Devarati Mitra; Fiscal Year: 2013
    ..Finally, the ROS burden in melanocytes will be genetically and pharmacologically altered to investigate if this strategy can block red/blond-melanoma induction. ..
  38. Farrukh Afaq; Fiscal Year: 2014
    ....
  39. Melanocyte Survival and Transformation: Hypoxia & P13 Kinase/Akt/mTOR Signaling
    Marianne Broome Powell; Fiscal Year: 2010
    ....
  40. TAS:: 75 0850 ::TAS RECOVERY ACT - ACTNOW CLINICAL TRIAL 8461
    David P Kelsen; Fiscal Year: 2009
    ....
  41. Keiran Smalley; Fiscal Year: 2015
    ..It is expected that knowledge gained from this work will provide novel therapeutic strategies for overcoming BRAF inhibitor resistance in the clinic. 1 ..
  42. Somatic genetic predictors of response to therapy in metastatic melanoma
    Katherine L Nathanson; Fiscal Year: 2011
    ..These aims will provide valuable information about selecting patients with melanoma for targeted therapies and provide a basis for further therapeutic development. ..
  43. Augmenting Melanoma Response to B-Raf V600E Targeting
    Roger S Lo; Fiscal Year: 2012
    ..By understanding the factors determining drug sensitivity and key mechanisms of acquired resistance, we can design better therapies to treat this deadly skin cancer. ..
  44. Sarah K Nelson; Fiscal Year: 2016
    ..Following the completion of my Ph.D. degree, I will return to the University Of Colorado School Of Medicine to complete my medical coursework and clinical rotations. ..
  45. Combination immunotherapies for the treatment of melanoma
    Michael W Fanger; Fiscal Year: 2013
    ....
  46. Nancy E Thomas; Fiscal Year: 2014
    ....
  47. Miriam Merad; Fiscal Year: 2016
    ..Combination therapy with BRAF inhibitors and immunotherapy is urgently needed by melanoma patients. Results of this study are expected to provide a rationale for the design of key clinical trials to treat this devastating disease. ..
  48. Martin McMahon; Fiscal Year: 2016
    ....
  49. Julie S Barber-Rotenberg; Fiscal Year: 2015
    ..The inhibitors may also form lead compounds for future drug development for the treatment of melanoma and other cancer types. ..
  50. CHRISTIE ANNE CIARLO; Fiscal Year: 2015
    ....
  51. Akt3 Signaling as a Therapeutic Target
    Gavin P Robertson; Fiscal Year: 2012
    ..Therefore, the positive impact of this study on the melanoma therapeutics field will be significant. ..
  52. Diagnosing Emergence of Kinase Inhibitor Resistance on a Microchip
    Thomas G Graeber; Fiscal Year: 2013
    ..Graeber, H.-R. Tseng, R. Lo and A. Ribas), make the melanoma microfluidic diagnostic approach uniquely positioned to impact ongoing clinical trials and therapy. ..
  53. Regulation of LKB1 and AMPK Signaling by BRAF in Melanoma
    Bin Zheng; Fiscal Year: 2012
    ..The advisory committee and the vibrant scientific environment at the Columbia University Medical Center will facilitate Dr. Zheng in achieving his scientific and career goals. ..
  54. Clinical Investigation in Tumor Immunotherapy
    Jeffrey A Sosman; Fiscal Year: 2012
    ..The K24 activities will be integrated with the T32, K12 training grants, and the MSCI courses. ..
  55. Christopher M Snyder; Fiscal Year: 2014
    ..Here we will test the efficacy of CMV-based vaccination in the presence or absence of Vemurafenib inhibition of BRAF, with specific focus on T cell infiltration of tumors and function within tumors. ..
  56. Jessie Villanueva; Fiscal Year: 2016
    ..Collectively, this knowledge will be critical to develop new strategies that eliminate nearly all melanoma cells and inform the design of future clinical trials. ..
  57. David E Fisher; Fiscal Year: 2016
    ..abstract_text> ..
  58. Jeffrey W Smith; Fiscal Year: 2016
    ..abstract_text> ..
  59. MATTHEW WAYNE VANBROCKLIN; Fiscal Year: 2016
    ....
  60. Hsian Rong Tseng; Fiscal Year: 2015
    ....
  61. Jennifer A Wargo; Fiscal Year: 2016
    ..abstract_text> ..
  62. Andrew E Aplin; Fiscal Year: 2016
    ..At the completion of our experiments, we expect to have identified a novel resistance-promoting mechanism and provided evidence for utilizing FOXD3 and/or ERBB3 as a biomarker for B-RAF inhibitor resistant melanoma cells. ..
  63. CHRYSTAL MARY PAULOS; Fiscal Year: 2016
    ..Overall, the proposed research is expected to demonstrate that manipulation of the Th17 ICOS pathway may sufficiently induce durable protection against the recurrence of advanced malignancies. ..
  64. Ze ev A Ronai; Fiscal Year: 2015
    ..Our proposed studies provide an unprecedented opportunity to establish the importance of PDK1 in melanoma development and its potential as novel therapeutic modality. ..
  65. MEENHARD F HERLYN; Fiscal Year: 2016
    ..To account for the increased needs for compound synthesis and modification, we have added a Medicinal Chemistry Core (D) in this renewal application. ..
  66. Rina Plattner; Fiscal Year: 2016
    ....
  67. Neal Rosen; Fiscal Year: 2015
    ....
  68. Roger S Lo; Fiscal Year: 2016
    ..Translating knowledge of how melanomas resist BRAF inhibitors back to the clinic promises to make the 2010 melanoma turning point a story for the ages. ..
  69. Christopher M Counter; Fiscal Year: 2014
    ....
  70. NOVEL SECOND MESSENGER SIGNALING IN THE STRIATUM
    ANN GRAYBIEL; Fiscal Year: 2003
    ..Understanding these novel second messenger signaling molecules will therefore bring insights to understanding fundamentally important brain functions and will help in elucidating brain disorders. ..
  71. ANDREW ANDREW FUTREAL; Fiscal Year: 2015
    ....
  72. Genetics of RAS, PTEN, BRAF and CDKN2A in Melanoma
    Philip Hinds; Fiscal Year: 2009
    ..And fourth, we will develop genetic techniques using RNA interference to test strategies for melanoma inhibition and pharmacological therapy. ..
  73. GAB2 in metastatic melanoma
    Julide T Celebi; Fiscal Year: 2013
    ..This proposal involves studying the contribution of GAB2 in melanoma to provide a basis whether its targeting would be therapeutically beneficial. ..
  74. Regulation of LKB1 and AMPK Signaling by BRAF in Melanoma
    Bin Zheng; Fiscal Year: 2009
    ..This research will provide the molecular basis for future targeted therapies for melanoma. ..
  75. Development of Inhibitors of B-Raf to Treat Melanoma
    NEAL BIRNBERG; Fiscal Year: 2004
    ....
  76. REGULATION OF SODIUM CHANNEL EXPRESSION
    ROBERT MAUE; Fiscal Year: 2000
    ....
  77. Development of a Urine Test for the Early Detection of Colon Cancer
    Wei Song; Fiscal Year: 2012
    ..The goal of this phase I project is to explore the ability of a urine DNA test to detect early stages of colon cancer by analyzing colon cancer-associated genetic and epigenetic modifications. ..